1.The cephalosporin market has fallen through the 57billion Chengdu Beite new 1billion echelon!
Cephalosporins are commonly used in clinical medicine and the Top1 sub category of systemic anti-bacterial drugs. In recent years, cephalosporins have also become a “frequent customer” of national centralized procurement. Under the influence of multiple policies, the sales scale of cephalosporins in the terminals of public medical institutions in China fell again in 2021, falling below 57billion yuan. The sales of injections have recovered and their proportion has increased. The pattern of many enterprises of domestic varieties that have entered the national collection has changed dramatically. The generic drug market is speeding up “vacating space”; In recent years, the R & D direction of domestic pharmaceutical enterprises has focused on the new dosage forms of compound preparations and powder liquid double chamber bags, and a number of potential new products are ready to go.
2.Oseltamivir is no longer popular, and the pattern of anti influenza drugs is reversed!
The latest influenza weekly report (6.6-6.12) of the National Influenza Center on June 17 showed that the proportion of influenza like cases (ili%) in outpatient cases reported by sentinel hospitals in southern provinces was 5.8%, higher than the level of the previous week (5.1%), higher than the level of the same period in 2019-2021 (4.4%, 3.0% and 4.3%), significantly higher than the level of influenza like cases (ili%) in outpatient cases in the same period in the influenza outbreak season in 2019. According to the latest data of the World Health Organization’s global influenza monitoring and response system, since 2022, the incidence of influenza in the northern and southern hemispheres has rebounded significantly. Since June, Fujian, Guangdong, Hainan, Jiangxi and other places have successively issued emergency warnings. The number of fever outpatient visits in some medical institutions has increased, and many places in the South have entered the peak of influenza in summer.
3.Encourage and promote R & D and innovation and accelerate the accessibility of children’s medication in China.
The selection work of the clinical expert advisory committee for the technical evaluation of children’s medication was launched, and the technical guidelines for the design and evaluation of the taste of children’s medication, the application for communication and management procedures for children’s medication were publicly solicited for comments… Recently, a series of positive signals encouraging the research, development and production of children’s medication have attracted the attention of the industry.
4.$36.7 billion star drugs topped the list, and omeprazole and other chronic diseases ended!
With the passage of time, the structure of the global drug market has undergone earth shaking changes. Omeprazole, simvastatin, atorvastatin and other heavy drugs for chronic diseases, which swept the world 21 years ago and were listed as best-selling drugs, have disappeared, and are replaced by adalimumab, pabolizumab and other anti-tumor and immunosuppressants. In the era of the prevalence of centralized procurement and the rise of the generic pharmaceutical market, domestic pharmaceutical enterprises began to find another way out, innovate and transform, and crowded into the track of innovative drugs one after another. Grasping the direction of the development of the pharmaceutical market will become the key secret for enterprises to stand out.
5.Inhalant burst! Top10 products in the 25billion market rose sharply.
Recently, terbutaline inhaler was officially included in the seventh batch of centralized procurement, and domestic substitution is expected to speed up. According to the data of Intranet, the sales of terminal inhalants in public medical institutions in China exceeded 25 billion yuan in 2021, with a year-on-year increase of 26.75%. The sales of TOP10 products have achieved positive growth, and budesonide suspension for inhalation has ranked first in a row. Among TOP10 brands, four domestic brands such as Hengrui and Zhengda Tianqing have been listed. 10 inhalants have been evaluated, and privet and jiankangyuan have led the list, and more than 10 inhalants are under research respectively.
6.National Health Commission: the average life expectancy in China has increased to 77.93 years.
On the 5th, the National Health Commission held a press conference on the progress and effectiveness of the healthy China action since its implementation. Mao Qunan, deputy director of the office of the healthy China action Promotion Committee and director of the planning department of the National Health Commission, said at the meeting that at present, China’s per capita life expectancy has increased to 77.93 years old, the main health indicators are in the forefront of middle and high-income countries, and the 2020 phased goals of the “healthy China 2030″ plan outline have been achieved on schedule, The main objectives of the healthy China action in 2022 were achieved ahead of schedule, and the construction of a healthy China started well and progressed smoothly, playing an important role in building a moderately prosperous society in all respects and promoting the economic and social development of the 14th five year plan.
7.National Health Commission: the average life expectancy of Chinese residents has increased to 78.2 years.
The National Health Commission today released a statistical bulletin on the development of health care in 2021. The bulletin shows that the average life expectancy of Chinese residents has increased from 77.93 years in 2020 to 78.2 years in 2021, the maternal mortality rate has decreased from 16.9/100000 to 16.1/100000, and the infant mortality rate has decreased from 5.4 ‰ to 5.0 ‰.
JinDun Medical has long-term scientific research cooperation and technology grafting with Chinese universities. With Jiangsu’s rich medical resources, it has long-term trade relations with India, Southeast Asia, South Korea, Japan and other markets. It also provides market and sales services in the whole process from intermediate to finished product API. Utilize the accumulated resources of Jindun Chemical in fluorine chemistry to provide special chemical customization services for partners. Provide process innovation and impurity research services to target customers.
Post time: Nov-11-2022